Rimegepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials
Background: Migraine is a leading cause of global disability, often requiring effective preventive strategies to reduce disease burden and improve patient quality of life. Rimegepant is an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist. Although its efficacy in the acute treatment of mig...